Alkermes (ALKS) Other Non-Current Assets (2011 - 2026)
Alkermes (ALKS) reported Other Non-Current Assets of $59.4 million for Q1 2026, up 223.14% year-over-year from $18.4 million in Q1 2025, and up 20.89% quarter-over-quarter from $49.1 million in Q4 2025.
Alkermes (ALKS) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Other Non-Current Assets data on file, last reported at $59.4 million in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $59.4 million, up 223.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.4 million (up 223.14% YoY), and the FY2025 annual result was $49.1 million, up 197.52% from the prior year.
- Other Non-Current Assets climbed to $59.4 million in Q1 2026 per ALKS's latest filing, from $49.1 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $59.4 million in Q1 2026 and troughed at $10.7 million in Q1 2022.
- A 5-year average of $20.6 million and a median of $16.3 million in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2026: Other Non-Current Assets slumped 69.49% in 2023, then surged 223.14% in 2026.
- A 5-year view of Other Non-Current Assets shows it stood at $37.8 million in 2022, then tumbled by 69.49% to $11.5 million in 2023, then jumped by 43.24% to $16.5 million in 2024, then surged by 197.52% to $49.1 million in 2025, then rose by 20.89% to $59.4 million in 2026.
- Business Quant data shows ALKS's Other Non-Current Assets at $59.4 million in Q1 2026, $49.1 million in Q4 2025, and $19.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 1.79 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 351.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 233.20 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 3.45 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 73.60 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 295.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 59.36 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 47.63 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 3.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.36 Mn |
| Dec 31, 2025 | 49.10 Mn |
| Sep 30, 2025 | 19.66 Mn |
| Jun 30, 2025 | 19.91 Mn |
| Mar 31, 2025 | 18.37 Mn |
| Dec 31, 2024 | 16.50 Mn |
| Sep 30, 2024 | 16.80 Mn |
| Jun 30, 2024 | 16.30 Mn |
| Mar 31, 2024 | 11.52 Mn |
| Dec 31, 2023 | 11.52 Mn |
| Sep 30, 2023 | 11.29 Mn |
| Jun 30, 2023 | 14.54 Mn |
| Mar 31, 2023 | 14.91 Mn |
| Dec 31, 2022 | 37.76 Mn |
| Sep 30, 2022 | 10.98 Mn |
| Jun 30, 2022 | 11.57 Mn |
| Mar 31, 2022 | 10.66 Mn |
| Dec 31, 2021 | 27.46 Mn |
| Sep 30, 2021 | 16.77 Mn |
| Jun 30, 2021 | 17.40 Mn |